Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/Wellcome TPA litigation

Executive Summary

On Oct. 31, the British Court of Appeals rejected Genentech's broad patent claims covering its clot dissolver, TPA. The decision upholds an earlier lower court ruling. Genentech said it does not believe the decision will affect Genentech's TPA patent position in the U.S. Genentech has been in litigation with Wellcome since Genentech was granted a U.K. patent and a subsequent U.S. recombinant patent. Genentech has a patent infringement suit against Wellcome pending in Delaware Federal Court ("The Pink Sheet" Aug. 29, T&G-8).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel